ESSA Pharma Stock Today

EPIX Stock  USD 2.97  0.08  2.62%   

Market Performance

8 of 100

Odds Of Distress

Less than 49

ESSA Pharma is trading at 2.97 as of the 23rd of March 2023; that is -2.62 percent down since the beginning of the trading day. The stock's open price was 3.05. ESSA Pharma has 49 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for ESSA Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of April 2021 and ending today, the 23rd of March 2023. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
9th of July 2015
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Essa Pharma is traded on NASDAQ Exchange in the United States.. The company has 44.09 M outstanding shares of which 236.8 K shares are currently shorted by private and institutional investors with about 1.12 trading days to cover. More on ESSA Pharma

Moving together with ESSA Pharma

+0.73MGTAMagenta Therapeutics Earnings Call TodayPairCorr
+0.65MIRMMirum Pharmaceuticals Fiscal Quarter End 31st of March 2023 PairCorr
+0.75MORFMorphic Holding Fiscal Quarter End 31st of March 2023 PairCorr
+0.7MRUSMerus BV Fiscal Quarter End 31st of March 2023 PairCorr
+0.87VRCAVerrica Pharmaceuticals Fiscal Quarter End 31st of March 2023 PairCorr

Moving against ESSA Pharma

-0.69ENOBEnochian BiosciencesPairCorr
-0.66NBIXNeurocrine Biosciences Fiscal Quarter End 31st of March 2023 PairCorr
-0.61MRNAModerna Fiscal Quarter End 31st of March 2023 PairCorr
-0.56OCGNOcugen Inc Fiscal Quarter End 31st of March 2023 PairCorr

ESSA Pharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ESSA Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ESSA Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO and President and DirectorDavid MD
Fama & French Classification
Average Analyst Recommendation
Analysts covering ESSA Pharma report their recommendations after researching ESSA Pharma's financial statements, talking to executives and customers, or listening in on ESSA Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering ESSA Pharma. The ESSA Pharma consensus assessment is calculated by taking the average forecast from all of the analysts covering ESSA Pharma.
Strong Buy4 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of ESSA Pharma based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of ESSA Pharma financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted54.6 M50.6 M
Significantly Up
Slightly volatile
Weighted Average Shares54.6 M50.6 M
Significantly Up
Slightly volatile
Current Liabilities3.1 M2.7 M
Fairly Up
Slightly volatile
Total Liabilities3.3 M2.1 M
Way Up
Very volatile
Total Debt194.2 K189.2 K
Fairly Up
Slightly volatile
Current Assets209.8 M194.4 M
Significantly Up
Slightly volatile
Total Assets210.3 M194.9 M
Significantly Up
Slightly volatile
Macroaxis Advice
The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of ESSA Pharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
ESSA Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ESSA Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ESSA Pharma's financial leverage. It provides some insight into what part of ESSA Pharma's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on ESSA Pharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how ESSA Pharma deploys its capital and how much of that capital is borrowed.
ESSA Pharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 242.14 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. ESSA Pharma has a current ratio of 42.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ESSA Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, ESSA Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ESSA Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ESSA Pharma to invest in growth at high rates of return. When we think about ESSA Pharma's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(26.51 Million)
ESSA Pharma (EPIX) is traded on NASDAQ Exchange in USA. It is located in 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5 and employs 50 people. ESSA Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 131.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ESSA Pharma's market, we take the total number of its shares issued and multiply it by ESSA Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ESSA Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 44.09 M outstanding shares of which 236.8 K shares are currently shorted by private and institutional investors with about 1.12 trading days to cover. ESSA Pharma currently holds about 174.6 M in cash with (28.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ESSA Pharma Probability Of Bankruptcy
ESSA Pharma retains a total of 44.09 Million outstanding shares. The majority of ESSA Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in ESSA Pharma to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in ESSA Pharma. Please pay attention to any change in the institutional holdings of ESSA Pharma as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation

Check ESSA Pharma Ownership Details

ESSA Pharma Stock Price Odds Analysis

Based on a normal probability distribution, the odds of ESSA Pharma jumping above the current price in 90 days from now is about 35.56%. The ESSA Pharma probability density function shows the probability of ESSA Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.3016 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ESSA Pharma will likely underperform. Additionally, the company has an alpha of 0.1962, implying that it can generate a 0.2 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 2.97HorizonTargetOdds Above 2.97
64.30%90 days
Based on a normal probability distribution, the odds of ESSA Pharma to move above the current price in 90 days from now is about 35.56 (This ESSA Pharma probability density function shows the probability of ESSA Pharma Stock to fall within a particular range of prices over 90 days) .

ESSA Pharma Historical Income Statement

ESSA Pharma Income Statement is one of the three primary financial statements used for reporting ESSA Pharma's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ESSA Pharma revenue and expense. ESSA Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
ESSA Pharma Interest Expense is fairly stable at the moment as compared to the past year. ESSA Pharma reported Interest Expense of 12,371.4 in 2022. Operating Expenses is likely to rise to about 45.9 M in 2023, whereas Consolidated Income is likely to drop (32.4 M) in 2023. View More Fundamentals

ESSA Pharma Stock Against Markets

Picking the right benchmark for ESSA Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ESSA Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ESSA Pharma is critical whether you are bullish or bearish towards ESSA Pharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in ESSA Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run My Watchlist Analysis Now


My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch Module

ESSA Pharma Corporate Directors

ESSA Pharma corporate directors refer to members of an ESSA Pharma board of directors. The board of directors generally takes responsibility for the ESSA Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of ESSA Pharma's board members must vote for the resolution. The ESSA Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Gary SollisIndependent DirectorProfile
Marianne SadarChief Scientific Officer and DirectorProfile
Franklin BergerIndependent DirectorProfile
Raymond AndersenChief Technical Officer, Secretary and DirectorProfile

How to buy ESSA Pharma Stock?

Before investing in ESSA Pharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in ESSA Pharma. To buy ESSA Pharma stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of ESSA Pharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase ESSA Pharma stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located ESSA Pharma stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased ESSA Pharma stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as ESSA Pharma, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy ESSA Pharma Stock please use our How to Invest in ESSA Pharma guide.

Already Invested in ESSA Pharma?

The danger of trading ESSA Pharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ESSA Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ESSA Pharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ESSA Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Investing Opportunities. For more information on how to buy ESSA Pharma Stock please use our How to Invest in ESSA Pharma guide. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for analysis

When running ESSA Pharma price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA Pharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA Pharma that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine ESSA Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.